By the same authors

From the same journal

From the same journal

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

Research output: Contribution to journalLiterature review

Full text download(s)

Links

Author(s)

Department/unit(s)

Publication details

JournalHealth technology assessment
DatePublished - May 2005
Issue number15
Volume9
Number of pages158
Original languageEnglish

Abstract

The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

    Research areas

  • ADD-ON THERAPY, QUALITY-OF-LIFE, REFRACTORY PARTIAL EPILEPSY, NEWLY-DIAGNOSED EPILEPSY, COMPLEX PARTIAL SEIZURES, PLACEBO-CONTROLLED TRIAL, PARTIAL-ONSET SEIZURES, RESISTANT PARTIAL EPILEPSY, GAMMA-VINYL-GABA, VISUAL-FIELD DEFECTS

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations